Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial
- PMID:16361021
- DOI: 10.1016/S1474-4422(05)70253-2
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial
Abstract
Background: Traumatic brain injury is a major cause of death and disability. We sought to assess the safety and efficacy of dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity, in severe traumatic brain injury.
Methods: 861 patients with severe traumatic brain injury admitted to 86 specialist centres from 15 countries were included in a multi-centre, placebo-controlled, phase III trial. Patients were randomised to receive a single intravenous 150 mg dose of dexanabinol or placebo within 6 h of injury. The primary outcome was the extended Glasgow outcome scale assessed at 6 months, with the point of dichotomisation into unfavourable versus favourable outcome differentiated by baseline prognostic risk. Prespecified subgroup analyses were defined by injury severity, recruitment rate, and time to dosing. Secondary analysis included control of intracranial pressure and quality of life. Analysis were prespecified in the protocol and the statistical analysis plan. This study is registered with ClinicalTrials.gov, numberNCT00129857.
Findings: 846 patients were included in the efficacy analysis. The extended Glasgow outcome scale at 6 months did not differ between groups; 215 (50%) patients in the dexanabinol group and 214 (51%) patients in the placebo group had an unfavourable outcome (odds ratio for a favourable response 1.04; 95% CI 0.79-1.36). Improvements in the control of intracranial pressure or quality of life were not recorded and subgroup analysis showed no indication of differential treatment effects. Dexanabinol was not associated with hepatic, renal, or cardiac toxic effects.
Interpretation: Dexanabinol is safe, but is not efficacious in the treatment of traumatic brain injury.
Similar articles
- Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A.Knoller N, et al.Crit Care Med. 2002 Mar;30(3):548-54. doi: 10.1097/00003246-200203000-00009.Crit Care Med. 2002.PMID:11990913Clinical Trial.
- Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group.Marmarou A, Nichols J, Burgess J, Newell D, Troha J, Burnham D, Pitts L.Marmarou A, et al.J Neurotrauma. 1999 Jun;16(6):431-44. doi: 10.1089/neu.1999.16.431.J Neurotrauma. 1999.PMID:10391361Clinical Trial.
- Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial.Temkin NR, Anderson GD, Winn HR, Ellenbogen RG, Britz GW, Schuster J, Lucas T, Newell DW, Mansfield PN, Machamer JE, Barber J, Dikmen SS.Temkin NR, et al.Lancet Neurol. 2007 Jan;6(1):29-38. doi: 10.1016/S1474-4422(06)70630-5.Lancet Neurol. 2007.PMID:17166799Clinical Trial.
- Dexanabinol: a novel cannabinoid with neuroprotective properties.Darlington CL.Darlington CL.IDrugs. 2003 Oct;6(10):976-9.IDrugs. 2003.PMID:14534855Review.
- [Value of serial CT scanning and intracranial pressure monitoring for detecting new intracranial mass effect in severe head injury patients showing lesions type I-II in the initial CT scan].Lobato RD, Alen JF, Perez-Nuñez A, Alday R, Gómez PA, Pascual B, Lagares A, Miranda P, Arrese I, Kaen A.Lobato RD, et al.Neurocirugia (Astur). 2005 Jun;16(3):217-34.Neurocirugia (Astur). 2005.PMID:16007322Review.Spanish.
Cited by
- New horizons for newborn brain protection: enhancing endogenous neuroprotection.Hassell KJ, Ezzati M, Alonso-Alconada D, Hausenloy DJ, Robertson NJ.Hassell KJ, et al.Arch Dis Child Fetal Neonatal Ed. 2015 Nov;100(6):F541-52. doi: 10.1136/archdischild-2014-306284. Epub 2015 Jun 10.Arch Dis Child Fetal Neonatal Ed. 2015.PMID:26063194Free PMC article.Review.
- Cannabinoid-based medicines for neurological disorders--clinical evidence.Wright S.Wright S.Mol Neurobiol. 2007 Aug;36(1):129-36. doi: 10.1007/s12035-007-0003-4. Epub 2007 Jun 29.Mol Neurobiol. 2007.PMID:17952657Review.
- Cannabis products: medical use.Fernandes CE, Dolci JEL, Navarro LS, Allevato M, Constantino CF, Pereira RPA, Rieder CRM, Torino F, Bernardo WM.Fernandes CE, et al.Rev Assoc Med Bras (1992). 2023 Mar 10;69(3):358-364. doi: 10.1590/1806-9282.2023D693. eCollection 2023.Rev Assoc Med Bras (1992). 2023.PMID:36921194Free PMC article.No abstract available.
- Cannabinoids in health and disease.Kogan NM, Mechoulam R.Kogan NM, et al.Dialogues Clin Neurosci. 2007;9(4):413-30. doi: 10.31887/DCNS.2007.9.4/nkogan.Dialogues Clin Neurosci. 2007.PMID:18286801Free PMC article.Review.
- Interactions of oxidative stress and neurovascular inflammation in the pathogenesis of traumatic brain injury.Abdul-Muneer PM, Chandra N, Haorah J.Abdul-Muneer PM, et al.Mol Neurobiol. 2015;51(3):966-79. doi: 10.1007/s12035-014-8752-3. Epub 2014 May 28.Mol Neurobiol. 2015.PMID:24865512Free PMC article.Review.
Publication types
MeSH terms
Substances
Associated data
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources